Nova Laboratories has announced the European Commission approval of new Xaluprine oral formulation without the preservative propyl parabens.
Supplied from January 2013, revised formulation is indicated for acute lymphoblastic leukaemia and is free from artificial colours, artificial flavours and sugar.
According to the company, the medication available in natural raspberry flavor is easier for patients consummation.
Xaluprine was developed to enable steady absorption and is available in convenient doses even from 2mg to meet precise individualized needs of the children.
Source:
http://drugdelivery.pharmaceutical-business-review.com/news/european-commission-approves-new-nova-xaluprine-oral-formulation-061212
